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Time to re-appraise the role of alpha-1 adrenoceptor
antagonists in the management of hypertension?
Neil Chapmana, Chung-Yin Chenb, Toshiro Fujitac, F.D. Richard Hobbsd,
Soo-Joong Kime, Jan A. Staessenf, Supachai Tanomsupg, Ji-Guang Wangh and
Bryan Williamsi
The role of alpha-1 adrenoceptor antagonists (alpha-
blockers) in the management of hypertension continues
to evolve. Recent data support their use as add-on
therapy in uncontrolled hypertension when used in
combination with all other major classes of
antihypertensive drug and there is increasing evidence
suggesting that they have modest but significant
beneficial effects on lipid and glucose metabolism. The
availability of extended-release formulations has
contributed to an excellent tolerability profile. New data
from an observational analysis of the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) suggest that doxazosin
gastrointestinal therapeutic system (GITS) used as a
third-line antihypertensive agent lowered blood pressure
and caused modest reductions in plasma lipids.
Furthermore, use of doxazosin in ASCOT was not
associated with an increased risk of heart failure, in
contrast to the earlier finding of the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Overall, currently available data support the
use of alpha-blockers as safe, well tolerated and effective
add-on antihypertensive drugs, which have additional
favourable metabolic effects. J Hypertens 28:1796–1803
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Wilkins.
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Introduction
Selective alpha-1 adrenoceptor antagonists (alpha-block-
ers) effectively lower blood pressure (BP) when used
either as monotherapy or in combination with other
drugs, including diuretics, beta-blockers, calcium chan-
nel blockers (CCBs) and angiotensin-converting enzyme
(ACE) inhibitors [1–9]. In addition, they have been
shown to have favourable effects on the metabolic pro-
files of patients with hypertension [3,4,10–19]. Beyond
hypertension, they have a role in relieving symptoms of
bladder outflow obstruction due to benign prostatic
hyperplasia [20].
The Antihypertensive and Lipid-Lowering to Prevent
Heart Attack Trial (ALLHAT) suggested that doxazosin,
the most commonly used alpha-blocker, was associated
with less effective BP control than chlorthalidone when
used as first-line therapy. The doxazosin treatment arm of
the study was terminated prematurely due to a signifi-
cantly higher incidence of combinedmajor cardiovascular
disease events, particularly an increased risk of conges-
tive heart failure (CHF), among those randomized to
doxazosin compared with chlorthalidone [21]. Con-
sequently, in the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) guidelines,
alpha-blockers were not recommended for the routine
treatment of hypertension [22]. This has had a major
impact on their use for the treatment of hypertension
worldwide.
Recent data on the mechanism of action of alpha-block-
ers have emerged from experimental studies [23,24] and
new clinical studies have confirmed their BP-lowering
efficacy [25,26]. Results of an observational analysis
from the Anglo-Scandinavian Cardiac Outcomes Trial
1796 Review
0263-6352  2010 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI:10.1097/HJH.0b013e32833b912c
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
(ASCOT) [27] have demonstrated the effectiveness of
doxazosin and called into question the conclusions of the
ALLHAT investigators, prompting a reappraisal of the
role of alpha-blockers for the treatment of hypertension.
The clinical narrative review presents an update on the
evolving role of alpha-blockers in the management of
hypertension. Clinical data on all selective alpha-1 block-
ers are included, with most data available for doxazosin,
the principal reference agent for the class and the alpha-
blocker most commonly used for the treatment
of hypertension.
Mechanism of action of alpha-blockers
Cardiovascular regulation by the sympathetic nervous
system (SNS) is mediated via activation of one or more
subtypes of the adrenergic receptor family, including
alpha-1 and alpha-2 receptors, classified according to their
response to epinephrine and norepinephrine. Blockade of
alpha-1 receptors provides a rational approach to the
treatment of hypertension by inhibiting the binding of
noradrenaline, thereby promoting smooth muscle cell
relaxation, reduced vascular tone and decreased periph-
eral resistance [28]. Early tolerability issues, for example,
due to postural hypotension associated with unfavourable
pharmacokinetics of immediate-release drugs, have been
largely overcome by the development of controlled-
release formulations, such as prazosin and doxazosin
gastrointestinal therapeutic system (GITS) [29–32].
Such formulations have been designed to improve the
drugs’ pharmacokinetic profiles and to minimize side
effects by slowing absorption and reducing fluctuations
in plasma concentration [30]. The pharmacokinetic
characteristics of standard and long-acting formulations
of alpha-blockers commonly prescribed for the treatment
of hypertension are shown in Table 1 [29–32].
Alpha-blockers and blood pressure control
The BP-lowering effects of selective alpha-blockers have
been extensively studied, both as monotherapy and in
combination with other antihypertensive drug classes.
Studies of prazosin, terazosin, alfuzosin and doxazosin
have reported similar BP-lowering efficacy to other
therapies when used as monotherapy [1–8]. Following
12 weeks of treatment, standard-release formulations of
both prazosin and doxazosin decreased BP in approxi-
mately 70% of patients with hypertension, with no differ-
ence between treatments [1]. Alfuzosin (not licensed for
use in hypertension in the UK or US) was as effective as
propanolol when used first line [2]. In a large community-
based study, terazosin monotherapy significantly lowered
BP with similar efficacy to diuretics, beta-blockers, CCBs
and ACE inhibitors; among patients who had not
responded to monotherapy with these other drugs, the
addition of terazosin resulted in significant BP reductions
[3]. Prazosin GITS was shown to have similar BP-low-
ering efficacy to enalapril in patients with hypertension
and diabetes [4]. After 4 years of follow-up in the random-
ized Treatment of Mild Hypertension Study (TOMHS),
initial therapy with standard-release doxazosin (1–2mg
per day) reduced systolic and diastolic BP by 13.4 and
11.2mmHg, respectively, compared with mean
reductions of 8.6mmHg for both systolic and diastolic
BP among those who received placebo [5]. In a 12-week
placebo-controlled trial, the Doxazosin Investigators’
Study Group found that 68 and 64% of patients with
mild-to-moderate hypertension achieved BP targets with
standard (1–8mg per day) and GITS (4–8mg per day)
formulations of doxazosin, respectively, compared with
36% in the placebo group [6]. Other trials of doxazosin
monotherapy (both standard and GITS formulations)
have demonstrated significant BP reductions with a
favourable safety profile [7,8] and doxazosin has been
shown to be effective and well tolerated as add-on
therapy in uncontrolled hypertension [9].
The timing of doses of alpha-blockers may affect their
efficacy. Doxazosin GITS achieved more effective 24-h
BP control when administered (either as add-on or mono-
therapy) at night rather than in the morning [33]. In this
3-month study, a single dose of doxazosin GITS admi-
nistered at bedtime achieved significantly better 24-h BP
control compared with morning dosing, possibly by more
effectively reducing the prewaking activation of the SNS.
In a substudy of the Hypertension and Lipid Trial
(HALT), evening dosing with doxazosin reduced both
daytime and night-time systolic and diastolic BP, with
potentially favourable effects on nocturnal BP-dipping
patterns [34].
Metabolic actions of alpha-blockers
In addition to lowering BP, alpha-blockers have been
shown to exert a variety of potentially beneficial effects
on lipid and glucose metabolism. These include reduced
total cholesterol, low-density lipoprotein (LDL) choles-
terol and apolipoprotein (Apo) B concentrations, reduced
oxidation ofLDLcholesterol, increased high-density lipo-
protein (HDL) cholesterol and Apo A-1 concentrations,
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Table 1 Pharmacokinetic characteristics of standard and
long-acting formulations of selective alpha-1 receptor antagonists
Drug Characteristic Standard GITS
Terazosin [29] Tmax 1mg; 1.7 h –
Cmax 1mg; 15.5 ng/ml –
Prazosin [31] Mean residence
time
4mg; 10.8 h 2.5mg; 21.6 h
5mg; 22.5 h
Doxazosin [32] Tmax 4mg; 3.7 h 4mg; 8.2 h
8mg; 3.9 h 8mg; 9.1 h
Cmax 4mg; 29.3 ng/ml 4mg; 11.3 ng/ml
8mg; 66.8 ng/ml 8mg; 28.0 ng/ml
Cmin 4mg; 7.4 ng/ml 4mg; 6.4 ng/ml
8mg; 19.0 ng/ml 8mg; 17.8 ng/ml
Tmax, time to maximum concentration; Cmax, maximum concentration; Cmin, mini-
mum concentration; GITS, gastrointestinal therapeutic system.
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reduced hyperinsulinaemia and an improvement in glu-
cose tolerance [3,4,10–19].Themetabolic effects of alpha-
blockers used asmonotherapy in recent trials that included
at least 100 patients are summarized in Table 2. Favour-
able effects on lipid profiles have also been demonstrated
when alpha-blockers have been used in combination with
other classes of antihypertensive agents [3] and on insulin
sensitivity when used in combination with acarbose in
patients with impaired glucose tolerance [19]. The mol-
ecular mechanisms underlying the metabolic effects have
been explored and recent evidence suggests that doxazo-
sin may increase HDL cholesterol biosynthesis by mech-
anisms involving gene transcription that are independent
of its alpha-1 receptor antagonist properties [24].
Safety and tolerability of alpha-blockers
Alpha-blockers are generally well tolerated and have
similar adverse event profiles to other antihypertensive
agents [1–4]. Terazosin was well tolerated in more than
16 000 patients with a variety of concomitant diseases,
including CHF, peripheral vascular disease, chronic
obstructive pulmonary disease, diabetes and obesity
[3]. Adverse events were reported in 18% of patients,
most frequently dizziness (5%), headache (3%), and
asthenia (2%). Only 0.4 and 0.2% of patients experienced
syncope and impotence, respectively, and only 2%
dropped out of the study because of adverse events.
Standard-formulation doxazosin has an incidence of
adverse events similar to placebo, with minor adverse
effects such as headache and dizziness being most com-
monly reported [9,25]. In TOMHS, doxazosin compared
favourably with other antihypertensive drugs with regard
to erectile dysfunction in men; the incidence decreased
by 6% compared with a 10% increase among those
randomized to chlorthalidone [35]. Doxazosin GITS is
also well tolerated [7,8,26] with fewer discontinuations
than with the standard formulation or placebo [6].
The impact of ALLHAT
Antihypertensive and Lipid-Lowering Treatment to Pre-
vent Heart Attack Trial was designed to compare the
effects of chlorthalidone (a thiazide-like diuretic) with an
alpha-blocker (immediate-release doxazosin), a CCB
or an ACE inhibitor among hypertensive patients (aged
55 years with at least one other vascular risk factor)
[21]. Overall, 42 424 participants were randomized, of
whom 15 268 received chlorthalidone and 9067 received
doxazosin.
Follow-up was planned for 4–8 years. However, the
doxazosin arm of the trial was discontinued prematurely
following an interim data safety review. This decision was
based on a significantly higher incidence of combined
cardiovascular disease events (a secondary endpoint)
among participants in the doxazosin arm as well as a
low likelihood that a difference in the primary endpoint
would be observed by the scheduled trial end [21].
Chlorthalidone provided superior BP-lowering efficacy to
doxazosin at the doses used (12.5–25 and 2–8mg,
respectively) with systolic BP lower by an average of
3mmHg. Neither the primary endpoint of fatal CHD or
nonfatal myocardial infarction [relative risk (RR) 1.03,
95% confidence interval (CI), 0.90–1.17] nor total
mortality (RR 1.03, 95% CI 0.90–1.15) differed between
the two groups. However, major cardiovascular events
were 25%more frequent among those assigned doxazosin
(RR 1.25, 95% CI 1.17–1.33), a result driven by higher
rates of stroke (RR 1.19, 95% CI 1.01–1.40) and particu-
larly CHF (RR 2.04, 95% CI 1.79–2.32).
Interpretation of these data has varied widely. Some
concluded that doxazosin should be used only as add-
on therapy, whereas one editorial questioned even this
use [36]; others, meanwhile, questioned the rationale
behind early termination of the trial (which itself may
have exaggerated any true difference in outcomes
between treatment arms). It has been argued that the
observed effects on stroke (as well as some of the effect
on heart failure) are potentially consistent with the
observed BP differences [37], which themselves may
be related to the use of suboptimal doses of the short-
acting version of doxazosin.
The heart failure results in particular have provoked
much debate. Commentators have questioned the
validity of heart failure diagnoses, particularly given that
the high rates of heart failure observed (2.8 and 5.4% in
the chlorthalidone and doxazosin limbs, respectively
[21]) were not associated with excess mortality, either
in the doxazosin arm or in comparison to other studies
[37]. Heart failure was not an independent trial endpoint
and events were fully validated retrospectively only in a
small subgroup of 50 cases of fatal or hospitalized heart
failure. Among these relatively severe cases, there were
insufficient data for definitive review in 11 patients and
the diagnosis was confirmed in 33 of the remaining 39
cases (85%) [38]. Overall, therefore, the diagnosis of heart
failure was only validated in 66% of a sample of the most
serious cases and inaccuracies in diagnosis remains a
potential source of error. It has been postulated that
the early divergence of the event curves for heart failure
may represent the unmasking of symptoms of heart fail-
ure (e.g. peripheral oedema) due to withdrawal of drugs
(presumably mainly diuretics) in the 90% of participants
who were taking antihypertensive therapy prior to
randomization [37].
New data on blood pressure-lowering efficacy
of doxazosin GITS
In the randomized, double-blind Doxazosin GITS as
Add-on Therapy in Hypertension: an Efficacy and Safety
(GATES) Study, doxazosin GITS (4mg/day titrated to
8mg/day if required) or matched placebo was added to
existing antihypertensive therapy of patients with uncon-
trolled BP. After 6 weeks, BP control (<140/90mmHg)
1798 Journal of Hypertension 2010, Vol 28 No 9
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was achieved in 37.3% of those randomized to doxazosin
compared with 10.7% of those receiving placebo
(P< 0.001) [26]. The BP-lowering effects were observed
in combination with all major classes of antihypertensive
agents and the drug was well tolerated.
The ASOCIA (‘Add-on’) study was a prospective, open-
label, noncomparative study conducted among 3631
Spanish patients with uncontrolled hypertension. Partici-
pants received doxazosin GITS (4mg/day titrated to
8mg/day if required) in addition to existing medication.
The proportion reaching target BP (<140/90 mmHg) was
39% after 4 weeks, rising to 61% at week 16. The drug
was well tolerated with less than 3% of participants
reporting adverse events [39].
The Anglo-Scandinavian Cardiac Outcomes
Trial
Blood pressure-lowering efficacy
The Anglo-Scandinavian Cardiac Outcomes Trial was a
multicentre, international, randomized trial conducted
among 19 257 patients aged 40–79 years with hyperten-
sion and additional cardiovascular risk factors but no
history of CHD [40]. Participants were randomly
assigned an antihypertensive regimen based on either
amlodipine or atenolol in place of existing antihyperten-
sive medication. Perindopril or bendroflumethiazide
were added to each arm, respectively, in order to achieve
target BP (<140/90mmHg or <130/80mmHg in those
with diabetes). Doxazosin GITS could be added as a
common third-line antihypertensive agent (if BP
remained uncontrolled despite maximally tolerated
doses of first and second-line drugs) but its use was
not randomized.
Overall, 11 768 participants received doxazosin GITS. In
an observational database analysis, its effects were eval-
uated among 10 069 patients (mean age 63 years, 79%
male, 32% with diabetes) with valid BP measurements
before and during treatment [27]. Among this group,
doxazosin was initiated a median 8 months [interquartile
range (IQR) 3, 24] after randomization and was added to
an average of two other antihypertensive drugs; the mean
starting and final doses were 4 and 7mg, respectively.
During a median 12 (IQR 4, 31) months of uninterrupted
treatment (during which time there were no changes in
other antihypertensive drugs or doses), mean BP fell
from 159/89mmHg (SD 18/11) by almost 12/7mmHg
(SD 19/10, P< 0.0001). Significant reductions occurred
in all patient subgroups and target BP was achieved in
30%. Although these are uncontrolled data, they are
nevertheless consistent with other studies of doxazosin
GITS used as add-on antihypertensive therapy.
Metabolic effects
Analyses of lipid profiles included 2945 participants with
fasting blood samples taken before and during doxazosin
treatment, who took no lipid-lowering therapy and had no
changes in other antihypertensives between samples
[27]. During a median 9 months of uninterrupted
doxazosin therapy, there were significant reductions in
total cholesterol (0.28mmol/l; 4.7%), LDL-cholesterol
(0.21mmol/l; 5.5%) and triglycerides (0.17mmol/l;
9.1%), consistent with previous studies (see Table 2).
No change in HDL-cholesterol was observed.
The effects on fasting plasma glucose were analysed in
3409 patients without diabetes prior to starting doxazosin,
with fasting blood samples taken before and during
doxazosin treatment, and who had no changes in other
antihypertensives between samples. During a median 19
months uninterrupted doxazosin therapy, there was a
small but significant increase in fasting plasma glucose
(mean 0.11mmol/l; 3.5%). This finding contradicts
previous evidence that doxazosin exerts favourable
effects on insulin sensitivity and glucose levels [10–
12,18,19]. However, compared with those who did not
receive doxazosin in ASCOT, recipients of doxazosin had
higher systolic BP and fasting plasma glucose at study
entry and were more likely to have been randomized to
atenolol-based rather than amlodipine-based therapy, all
of which predicted new-onset diabetes among the whole
ASCOT cohort [41]; the observed rise may therefore
merely reflect the natural increase in glucose in such
a population.
Safety and tolerability
All 11 768 participants who received doxazosin GITS in
ASCOT contributed to analyses of safety and tolerability,
accumulating 39 996 patient-years of exposure to the drug
[27]. In total, 1055 adverse events in 877 participants
(7.5%) resulted in temporary or permanent discontinu-
ation of doxazosin. Of these, the most common events
were dizziness (29%), fatigue (13%), headache (9%),
vertigo (9%) and oedema (8%). Although the contribution
of each drug to the overall tolerability profile of the study
treatment regimen cannot be separated, these findings
are consistent with other clinical data regarding doxazosin
used as add-on therapy [9,26,39]. However, there still
remains a relative paucity of data on its long-term safety.
ASCOT, doxazosin and heart failure revisited
In ASCOT, heart failure was a prespecified secondary
endpoint with strict diagnostic criteria and all suspected
cases were evaluated rigorously by an independent end-
point committee. Crude heart failure rates were 1.51%
among those who received doxazosin at any point in the
trial and 1.54% among the remainder. Heart failure
occurred at a rate of 2.97/1000 person-years during dox-
azosin use, compared with 2.85/1000 person-years among
never users (rate ratio 1.04, 95% CI 0.80–1.36, P¼ 0.76).
In an analysis performed in case doxazosin was stopped
because of prodromal symptoms of heart failure (e.g.
oedema), the rate of heart failure occurring at any
point after initiation of doxazosin (whether or not it
1800 Journal of Hypertension 2010, Vol 28 No 9
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
was continued) was 3.34/1000 person-years (rate ratio
1.17, 95% CI 0.92–1.49, P¼ 0.20, compared with never
users) [27]. Therefore, although it should be reiterated
that these data are nonrandomized, there appeared to be
no excess of heart failure during almost 40 000 patient-
years exposure to doxazosin GITS. This was despite the
fact that recipients of doxazosin had more severe hyper-
tensive disease (higher systolic BP and prevalence of left
ventricular hypertrophy) at study entry than the rest of
the study population.
The apparent lack of an increased risk of heart failure in
ASCOT is at odds with the observation of a doubled risk
of CHF among those assigned doxazosin compared with
those assigned chlorthalidone in ALLHAT.Whether this
difference reflects the inadequacies of observational data
in ASCOT (including various possible sources of bias),
use of different formulations of doxazosin (modified-
release versus short-acting), differences between use of
doxazosin as third or first-line therapy, the presence in
each randomized arm of ASCOT of a drug systematically
used to treat heart failure (ACE inhibitors or diuretics),
the effect of withdrawal of existing diuretic therapy prior
to randomization in ALLHAT, or differences in the
validity of heart failure diagnosis remains unclear. How-
ever, whereas standard doxazosin used first-line may have
been less effective than chlorthalidone at reducing BP
and preventing stroke in ALLHAT, the use of the GITS
formulation as third-line therapy in ASCOT was not
associated with increased risk of heart failure.
Hypertension treatment guidelines: changing
perspectives
As the importance of achieving and maintaining increas-
ingly challenging BP goals has become more apparent in
recent years, guidelines have placed increased emphasis
placed on combination therapy. Currently, alpha-block-
ers have only a minor role in national and international
guidelines [22,42–45] (Table 3). Their status in future
guidelines is uncertain and may depend on greater con-
fidence by prescribers regarding their safety in the add-
on setting.
It is worth noting, however, that whereas alpha-blockers
may achieve greater endorsement as add-on therapy in
the future, confidence in beta-blockers as a first-line
option for uncomplicated hypertension is declining. This
is due to evidence that they may not be as effective as
other classes of drug in reducing cardiovascular events,
particularly stroke [46], and that their use is associated
with increased risk of developing new-onset diabetes,
particularly when used in combination with thiazide
diuretics [47]. This has been recognized in the National
Institute for Health and Clinical Excellence (NICE)
guidelines, which no longer recommend beta-blockers
as initial therapy in uncomplicated hypertension [45].
Conclusion
Selective alpha-1 blockers lower BP and, unlike many
other antihypertensives, have favourable effects on
plasma lipids and glucose. Recent data have provided
important information regarding their efficacy, safety and
metabolic benefits, particularly of modified release dox-
azosin used in the add-on setting. These data suggest that
doxazosin GITS is an effective third-line antihyperten-
sive when added to a range of other drugs, improves
plasma lipid profiles and is well tolerated. Recent evi-
dence also suggests that it is not associated with increased
risks of heart failure when used as add-on therapy.
Whereas the lack of morbidity and mortality outcome
data remains a major drawback, use of alpha-blockers
seems justified, particularly in the add-on setting and in
patients with metabolic complications such as dyslipi-
daemia or the metabolic syndrome.
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Table 3 Summary of major guidelines for use of alpha-1 adrenoceptor antagonists for hypertension
Guideline Year Recommendation for use of alpha-blockers
Seventh report of the Joint National Committee
on prevention, detection, evaluation and
treatment of high blood pressure (JNC 7) [22]
2003 Included in list of oral antihypertensive agents but place
in therapy not defined
Joint British Societies, guidelines on prevention
of cardiovascular disease in clinical practice (JBS-2) [42]
2005 Benign prostatic hyperplasia (BPH) listed as a
compelling indication
Caution advised in patients with postural hypotension
and heart failure
Contraindicated in urinary incontinence
European Society of Hypertension/European
Society of Cardiology (ESH/ESC) [43]
2007 Mentioned as frequently used add-on therapy
Benign prostatic hyperplasia listed as a specific indication
British Hypertension Society (BHS) [44] 2004 Recommended as 4th-line therapy
Benign prostatic hyperplasia listed as a compelling indication
National Institute for Health and Clinical Excellence (NICE) [45] 2006 Recommended as fourth-line therapy
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